Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $150 Price Target

Cantor Fitzgerald analyst Olivia Brayer reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral and maintains $150 price target.

BenzingaJul 1 20:50

"Interest rate cuts + Trump's return" two major expectations continue to ferment! Will this benefiting sector see the dawn?

Market participants believe that in recent three years, the biotechnology sector has been underperforming the broader market. Once the expectation of interest rate cuts is raised by the Fed, biotechnology companies, represented by innovative drugs, will have the ability to make up ground.

Futu NewsJul 1 20:07

Alnylam, Lilly, AstraZeneca Among Best Performing Pharmas, Biotechs in Q2

Seeking AlphaJul 1 08:30

Selling US$7.7m Of Alnylam Pharmaceuticals Stock Rewarded Insiders

Yahoo FinanceJun 29 19:00

Alnylam Pharmaceuticals Is Maintained at Buy by UBS

Alnylam Pharmaceuticals Is Maintained at Buy by UBS

Dow JonesJun 28 22:16

Express News | Alnylam Pharmaceuticals Inc : UBS Raises Target Price to $288 From $253

BreakingsJun 28 21:59